Tennr vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Healthcare fax automation AI extracting referral and authorization data into EHR workflows; eliminating manual fax processing for medical practices where 80% of communications are still faxed.
About
Tennr is an AI-powered healthcare operations platform that automates fax-based administrative workflows for healthcare providers — extracting data from incoming faxes (referrals, prior authorizations, lab results, patient records) and automatically routing, categorizing, and populating EHR workflows to eliminate the manual data entry that consumes significant administrative staff time at medical practices and health systems. Founded in 2021 and headquartered in New York, Tennr has raised approximately $18 million targeting the persistent problem of healthcare fax volume, as US healthcare still transmits approximately 80% of inter-provider communications via fax.\n\nTennr's AI system reads incoming fax documents, identifies the document type (referral, authorization request, clinical note), extracts key clinical data (patient name, DOB, diagnosis codes, requested procedures), and automatically creates the corresponding workflows in the practice management or EHR system — eliminating the need for front desk staff to manually read faxes, type data into multiple systems, and track follow-up actions. The platform integrates with major EHR systems (Epic, Athenahealth, eClinicalWorks) to push extracted data directly into the right fields.\n\nIn 2025, Tennr operates in the healthcare administrative AI market alongside Thoughtful AI (healthcare billing automation), Olive AI (now restructured), and general RPA platforms that healthcare organizations adapt for administrative workflows. The healthcare fax automation market is significant — large specialty practices can receive thousands of faxes daily, with each requiring manual processing. Tennr's AI-native approach for healthcare document understanding (trained specifically on medical fax content) differentiates it from generic document AI. The 2025 strategy focuses on expanding to more specialty practices, deepening integrations with more EHR platforms, and adding prior authorization automation as a high-value workflow.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.